The management of unstable angina and non-ST-segment elevation myocardial infarction

Minerva Cardioangiologica

Volumn 51, Issue 5, 2003, Pages 433-445

  Chen, A A ^a   Sabatine, M S ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angina, unstable; Angioplasty, transluminal, percutaneous coronary; Coronary disease, therapy; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN DERIVATIVE; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE SULFATE; NADROPARIN; NIFEDIPINE; NITRIC ACID DERIVATIVE; PROTAMINE; SILDENAFIL; THROMBIN; THROMBIN INHIBITOR; UNINDEXED DRUG; VERAPAMIL;

ANGIOCARDIOGRAPHY; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; NAUSEA; RESPIRATION DEPRESSION; REVIEW; RISK ASSESSMENT; ST SEGMENT; TACHYPHYLAXIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS; VOMITING;

ANGINA, UNSTABLE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; TIME FACTORS;

EID: 0348050064     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-8.
2. Gottlieb SO, Weisfeldt ML, Ouyang P, Achuff SC, Baughman KL, Traill TA et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation 1986;73:331-7.
3. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987;60:18A-25A.
4. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, 11: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-63.
5. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21:633-41.
6. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-9.
7. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985;5:717-22.
8. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988;319:385-92.
9. Effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial II - DAVIT II. Am J Cardiol 1990;66:779-85.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
11. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
12. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-8.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
14. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
15. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
16. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
17. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
18. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. RISC Group. Lancet 1990;336:827-30.
19. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-60.
20. Braunwald E, Antman EM, Beasley JW, Califf RM, Chettlin MD, Hochman JS et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardio-logy/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. (Available at http://www.acc.org/clinical/guidelines/unstable/unstable.pdf).
21. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CV, McFadden E et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809-40.
22. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
23. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89:81-8.
24. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;276:811-5.
25. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). [Circulation 1997;96:61-8. Erratum in: Circulation 1998;97:4131.
26. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). [Circulation 1997;96:61-8. Erratum in: Circulation 1998;97:4131.
27. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction (FRAXiparine in Ischaemic Syndrome). FRAX-IS Study Group. Eur Heart J 1999;20:1553-62.
28. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
29. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
30. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
31. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
32. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:701-7.
33. A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med 1996;335:775-82.
34. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999;353:429-38.
35. Antman EM, McCabe CH, Braunwald E, for the TIMI 8 Investigators. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. Am Heart J 2002;143:229-34.
36. White H, The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63.
37. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
38. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/ IIIa blockade (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.) The EPISTENT Investigators. Lancet 1998;352:87-92.
39. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM et al. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001;285:2468-73.
40. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) Trial Investigators. N Engl J Med 1998;339:436-43.
41. A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-505.
42. Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
43. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35. [Erratum in: Lancet 1997;350:744].
44. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35. [Erratum in: Lancet 1997;350:744].
45. Simoons ML, The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
46. Kereiakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391-5.
47. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
48. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9. [Erratum in: N Engl J Med 1999;341:548].
49. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9. [Erratum in: N Engl J Med 1999;341:548].
50. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-62.
51. Januzzi JL, Chae CU, Sabatine MS, Jang IK. Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis 2001;11:211-5.
52. Newby LK, Ohman EM, Christenson RH, Molitemo DJ, Harrington RA, White HD et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the Paragon-B troponin T substudy. Circulation 2001;103:2891-6.
53. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.
54. Sabatine MS, Januzzi JL, Snapinn S, Theroux P, Jang IK. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol 2001;88:488-92.
55. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223-9.
56. Morrow DA, Sabatine MS, Cannon CP, Theroux P. Benefit of tirofiban among patients treated without coronary intervention: application of the TIMI risk score for unstable angina/non-ST elevation MI in PRISM-PLUS. Circulation 2001;104 Suppl II:II-782.
57. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
58. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
59. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C et al. CREDO Investigators, Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. [Erratum in: JAMA 2003;289:9871.
60. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C et al. CREDO Investigators, Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. [Erratum in: JAMA 2003;289:9871.
61. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q wave myocardial infarction. Results of the TIMI IIIB Trial. Circulation 1994;89:1545-56.
62. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to ah invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92. [Erratum in: N Engl J Med 1998;339:1091].
63. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to ah invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92. [Erratum in: N Engl J Med 1998;339:1091].
64. Boden WE. "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes: management in the poststent/platelet inhibition era. J Am Coll Cardiol 2003;41: 113S-22S.
65. Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC-11) investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease. FRISC-II prospective randomized multicentre study. Lancet 1999;354:708-15.
66. Cannon CP, Weintraub WS, Demopoulos LA for the TACTICS-Thrombolysis In Myocardial Infraction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
67. Fox KA, Poole-Wilson PA, Henderson RA for the Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
68. Neumann F-J, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP et al. Evaluayion of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290:1593-9.
69. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67.
70. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750-8.
71. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
72. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999;83:1147-51.
73. Braunwald E. Unstable angina. A classification. Circulation 1989;80:410-4.
74. van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol 1995;25:1286-92.
75. Holmes DR Jr, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999;100:2067-73.
76. Cohen M, Hawkins L, Greenberg S, Fuster V. Usefulness of ST-segment changes in greater than of equal to 2 leads on the emergency room electrocardiogram in either unstable angina pectoris or non-Q-wave myocardial infarction in predicting outcome. Am J Cardiol 1991;67:1368-73.
77. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281:707-13.
78. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW et al. The electrocardiograin predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol 1997;30:133-40.
79. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein Ilb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA 2000;283:347-53.
80. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-9.
81. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41.
82. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary, syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149-56.
83. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
84. Sabatine MS, Morrow DA, DiBattiste PM et al. ST deviation and troponin provide independent prognostic and therapeutic information in UA/NSTEMI: Results from TACTICS-TIMI 18. Circulation 2002;106 (Suppl II):II-402.